Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey - Scorecard - MDSpire

Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey

  • By

  • Amrit Tiwana

  • Katherine A. Twohig

  • Mieke Fraser

  • Brooke Kinniburgh

  • Charlene Burmeister

  • Paul Choisil

  • Elizabeth Haywood

  • Dylan Griffith

  • Chloé G. Xavier

  • Alannah Hannigan

  • Kate Salters

  • Sofia R. Bartlett

  • February 23, 2026

  • 0 min

Share

Clinical Scorecard: Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey

At a Glance

CategoryDetail
ConditionSexually transmitted and bloodborne infections (STBBIs)
Key MechanismsIncreased prevalence among people who use substances (PWUS) due to sharing equipment and engaging in high-risk sexual behaviors.
Target PopulationPeople who use substances (PWUS), particularly young adults and men.
Care SettingCommunity-based harm reduction services, including overdose prevention and supervised consumption sites.

Key Highlights

  • PWUS have a significantly higher prevalence of STBBIs compared to the general population.
  • Barriers to STBBI testing include stigma, discrimination, and limited health literacy.
  • Community-based, low-barrier testing initiatives can improve testing uptake among PWUS.
  • Harm reduction services provide essential support and access to STBBI testing.
  • Strengthening early detection is critical to minimizing transmission and improving treatment linkage.

Guideline-Based Recommendations

Diagnosis

  • Implement routine STBBI testing in harm reduction settings.

Management

  • Utilize community-based approaches to facilitate access to testing and treatment.

Monitoring & Follow-up

  • Regularly assess testing uptake and barriers among PWUS.

Risks

  • Address the social determinants of health that contribute to STBBI vulnerability.

Patient & Prescribing Data

Individuals accessing harm reduction services in British Columbia.

Access to sterile equipment and testing can reduce transmission risks.

Clinical Best Practices

  • Provide low-barrier access to STBBI testing in harm reduction settings.
  • Train healthcare providers on addiction and STBBI care.
  • Engage PWUS in the design and implementation of testing services.

References

Original Source(s)

Related Content